<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In vitro studies suggest that haploinsufficiency is involved in the pathogenesis of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In patients with del5q cytogenetic abnormality, RPS-14 and microRNAs (miRNAs) play a major role </plain></SENT>
<SENT sid="2" pm="."><plain>In a multicenter phase II single-arm trial with lenalidomide in anemic primary del5q <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with low- or int-1 risk IPSS, biological changes from baseline were investigated </plain></SENT>
<SENT sid="3" pm="."><plain>Gene expression profiling of selected genes was performed (TaqMan® Low Density Array Fluidic card, Applied Biosystems PRISM® 7900HT) and normalized against the expression of the 18S housekeeping gene from a pool of healthy subjects </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-two patients were evaluated at baseline and after 3 and 6 months of treatment </plain></SENT>
<SENT sid="5" pm="."><plain>RPS-14, miR-145, and miR-146 were downregulated at baseline and significantly increased during treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Nuclear factor kappa B, IL-6, interferon regulatory factor-1, IFNγ-R2, IL-2, and many genes in the apoptotic pathways (TNF, IL-1B, and IL-10) were upregulated at baseline and significantly downregulated during lenalidomide treatment, while forkhead box P3, FAS, IFNγ, IL-12A, and IL-12B were downregulated at baseline and progressively upregulated during treatment </plain></SENT>
<SENT sid="7" pm="."><plain>The crucial role of aberrant immunological pathways and haploinsufficiency in the pathogenesis of del5q <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is confirmed in the present patient setting </plain></SENT>
<SENT sid="8" pm="."><plain>Our results indicate that lenalidomide may act through defined immunological pathways in this condition </plain></SENT>
</text></document>